Cadrenal Therapeutics Inc Sustainability Reports
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focused on developing cardiorenal therapeutics. Its lead pipeline product candidates include tecarfarin, an oral anticoagulant designed for patients with end-stage renal disease and atrial fibrillation.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
3 reports from 2022 to 2024
Company Profile
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focused on developing cardiorenal therapeutics. Its lead pipeline product candidates include tecarfarin, an oral anticoagulant designed for patients with end-stage renal disease and atrial fibrillation.
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
